Anna Ungvari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna Ungvari has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
Zoltan Ungvari
Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, USA
33 shared publicationsAndriy Yabluchanskiy
Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, USA
18 shared publicationsStefano Tarantini
Vascular Cognitive Impairment, Neurodegeneration and Healthy Brain Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, USA
18 shared publicationsBalázs Győrffy
Dept. of Bioinformatics, Semmelweis University, Budapest, Hungary
17 shared publicationsAnna Csiszar
Vascular Cognitive Impairment, Neurodegeneration and Healthy Aging Program, Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, USA
16 shared publicationsMónika Fekete
Institute of Preventive Medicine and Public Health, Semmelweis University, Budapest, Hungary
16 shared publications
Latest Publications
- Open Access
- 19 March 2026
- Published by Springer Nature in GeroScience
- Vol. 48 (3) , 5083-5084
Correction to: Clonal hematopoiesis of indeterminate potential (CHIP) in cerebromicrovascular aging: implications for vascular contributions to cognitive impairment and dementia (VCID)
- 19 March 2026
- Published by Springer Nature in GeroScience
- Vol. 48 (3) , 5083-5084
Open AccessCorrection to: Clonal hematopoiesis of indeterminate potential (CHIP) in cerebromicrovascular aging: implications for vascular contributions to cognitive impairment and dementia (VCID)
- Open Access
Age-Related Alterations of Cerebral Autoregulation
Intact regulation of cerebral blood flow (CBF) is essential for preserving cognitive function and reducing the risk of cerebrovascular events, particularly in the aging population. Autoregulation of CBF is one of the fundamental mechanisms that ensure constant supply for brain tissue by maintaining relatively stable perfusion despite fluctuations in systemic blood pressure. It also acts as a critical protective mechanism, shielding the fragile cerebral microcirculation from potentially harmful pressure fluctuations and hence excessive pulsatility. The loss or attenuation of this protective mechanism with aging or disease increases the vulnerability of the microvasculature to structural damage, blood–brain barrier (BBB) disruption, and the development of cerebral small vessel disease. This mini-review summarizes current understanding of how aging affects cerebral autoregulation, highlighting underlying mechanisms, clinical consequences, and potential strategies to preserve cerebrovascular health in older adults.
Open AccessAge-Related Alterations of Cerebral Autoregulation
Intact regulation of cerebral blood flow (CBF) is essential for preserving cognitive function and reducing the risk of cerebrovascular events, particularly in the aging population. Autoregulation of CBF is one of the fundamental mechanisms that ensure constant supply for brain tissue by maintaining relatively stable perfusion despite fluctuations in systemic blood pressure. It also acts as a critical protective mechanism, shielding the fragile cerebral microcirculation from potentially harmful pressure fluctuations and hence excessive pulsatility. The loss or attenuation of this protective mechanism with aging or disease increases the vulnerability of the microvasculature to structural damage, blood–brain barrier (BBB) disruption, and the development of cerebral small vessel disease. This mini-review summarizes current understanding of how aging affects cerebral autoregulation, highlighting underlying mechanisms, clinical consequences, and potential strategies to preserve cerebrovascular health in older adults.
- Open Access
- 26 October 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (1) , 951-971
Irradiation-induced brain senescence accelerates cardiac aging via systemic mechanisms: insights from transcriptomic profiling
Aging is characterized by a coordinated functional decline across multiple organs. While cell-autonomous mechanisms contribute to local aging phenotypes, the systemic synchronicity of aging suggests a major role for cell non-autonomous drivers. Emerging evidence implicates the hypothalamus—a central regulator of neuroendocrine and homeostatic functions—as a potential source of circulating pro-geronic signals. A hallmark of brain aging is the accumulation of senescent cells, particularly in microglia and brain microvascular endothelial cells, including within the hypothalamus, which contributes to a heightened state of neuroinflammation and altered systemic signaling. Here, we tested the hypothesis that brain senescence and its associated inflammatory milieu promote peripheral aging by reshaping the systemic environment. To model this, we employed targeted whole-brain irradiation (WBI) in young mice—a well-established method to induce widespread brain cellular senescence and neuroinflammation, mimicking changes seen in natural aging. Two months after WBI, we performed transcriptomic profiling of the heart to evaluate remote, cell non-autonomous effects. Cardiac RNA sequencing revealed a striking overlap in gene expression changes between WBI-treated young mice and naturally aged controls. Notably, several gene sets associated with fundamental cellular and molecular mechanisms of aging were concordantly dysregulated in both groups, with strong enrichment for pathways related to mitochondrial metabolism, immune activation, interferon signaling, and extracellular matrix remodeling. These findings demonstrate that localized brain senescence is sufficient to induce aging-like transcriptomic remodeling in peripheral organs, likely mediated by circulating factors. Our findings establish brain senescence as a key orchestrator of systemic aging—a mechanism that may contribute to accelerated aging trajectories in individuals with lifestyle-associated increased brain senescence and neuroinflammation, as well as in cancer survivors exposed to senescence-inducing treatments such as whole-brain irradiation.
- 26 October 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (1) , 951-971
Open AccessIrradiation-induced brain senescence accelerates cardiac aging via systemic mechanisms: insights from transcriptomic profiling
Aging is characterized by a coordinated functional decline across multiple organs. While cell-autonomous mechanisms contribute to local aging phenotypes, the systemic synchronicity of aging suggests a major role for cell non-autonomous drivers. Emerging evidence implicates the hypothalamus—a central regulator of neuroendocrine and homeostatic functions—as a potential source of circulating pro-geronic signals. A hallmark of brain aging is the accumulation of senescent cells, particularly in microglia and brain microvascular endothelial cells, including within the hypothalamus, which contributes to a heightened state of neuroinflammation and altered systemic signaling. Here, we tested the hypothesis that brain senescence and its associated inflammatory milieu promote peripheral aging by reshaping the systemic environment. To model this, we employed targeted whole-brain irradiation (WBI) in young mice—a well-established method to induce widespread brain cellular senescence and neuroinflammation, mimicking changes seen in natural aging. Two months after WBI, we performed transcriptomic profiling of the heart to evaluate remote, cell non-autonomous effects. Cardiac RNA sequencing revealed a striking overlap in gene expression changes between WBI-treated young mice and naturally aged controls. Notably, several gene sets associated with fundamental cellular and molecular mechanisms of aging were concordantly dysregulated in both groups, with strong enrichment for pathways related to mitochondrial metabolism, immune activation, interferon signaling, and extracellular matrix remodeling. These findings demonstrate that localized brain senescence is sufficient to induce aging-like transcriptomic remodeling in peripheral organs, likely mediated by circulating factors. Our findings establish brain senescence as a key orchestrator of systemic aging—a mechanism that may contribute to accelerated aging trajectories in individuals with lifestyle-associated increased brain senescence and neuroinflammation, as well as in cancer survivors exposed to senescence-inducing treatments such as whole-brain irradiation.
- Open Access
- 16 October 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (2) , 2029-2042
Mortality, functional outcome, and bleeding risk after early versus delayed thrombectomy
Endovascular thrombectomy (EVT) is an established treatment for acute ischemic stroke, due to large vessel occlusion (LVO), but the optimal time window for intervention remains a subject of ongoing debate. We aimed to assess the impact of treatment timing on mortality, functional outcomes, and safety by comparing early (≤ 6 h) versus late (> 6–24 h) EVT. We conducted a systematic review and meta-analysis to evaluate the effect of time to intervention on outcomes of endovascular thrombectomy (EVT) in acute ischemic stroke. Four databases (PubMed, Web of Science, Cochrane Library, and EMBASE) were searched for studies published between 2000 and 2024. Eligible randomized controlled trials and cohort studies reported on 90-day mortality, functional outcome (modified Rankin Scale, mRS), or symptomatic intracranial hemorrhage (sICH), stratified by treatment timing (≤ 6 h vs. > 6–24 h from symptom onset). Pooled incidence rates, incidence rate differences (IRD), and incidence rate ratios (IRR) were calculated using random-effects models. Eighteen studies met inclusion criteria. The pooled incidence of symptomatic intracranial hemorrhage (sICH) was 0.19 events per person-year (95% CI: 0.12–0.26) in the early group and 0.23 events per person-year (95% CI: 0.11–0.35) in the late group, with no significant difference between groups (incidence rate difference [IRD] − 0.028; p = 0.33, incidence rate ratio [IRR] 0.88; p = 0.33). For mortality, early EVT showed a significantly lower incidence rate of 0.66 events per person-year (95% CI: 0.51–0.82) compared to 0.77 events per person-year (95% CI: 0.63–0.91) in the late EVT group (IRD − 0.148; p = 0.0012, IRR 0.81; p = 0.0014). Functional independence was more frequent in the early group (1.72; 95% CI: 1.42–2.01) than in the late group (1.45; 95% CI: 0.91–1.98) (IRD 0.32; p < 0.0001, IRR 1.22; p < 0.0001). Heterogeneity was moderate to high across outcomes. The timing of endovascular thrombectomy significantly influences clinical outcomes in acute ischemic stroke. Our analysis shows that early intervention (within 6 h) is associated with a significantly lower mortality rate and a higher likelihood of achieving functional independence at 90 days compared to late intervention (beyond 6 up to 24 h). The incidence of symptomatic intracranial hemorrhage did not differ significantly between the groups, suggesting that late treatment does not increase safety risks. These findings underscore the importance of minimizing treatment delays, while also supporting the continued use of EVT in selected patients beyond the 6-h window.
- 16 October 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (2) , 2029-2042
Open AccessMortality, functional outcome, and bleeding risk after early versus delayed thrombectomy
Endovascular thrombectomy (EVT) is an established treatment for acute ischemic stroke, due to large vessel occlusion (LVO), but the optimal time window for intervention remains a subject of ongoing debate. We aimed to assess the impact of treatment timing on mortality, functional outcomes, and safety by comparing early (≤ 6 h) versus late (> 6–24 h) EVT. We conducted a systematic review and meta-analysis to evaluate the effect of time to intervention on outcomes of endovascular thrombectomy (EVT) in acute ischemic stroke. Four databases (PubMed, Web of Science, Cochrane Library, and EMBASE) were searched for studies published between 2000 and 2024. Eligible randomized controlled trials and cohort studies reported on 90-day mortality, functional outcome (modified Rankin Scale, mRS), or symptomatic intracranial hemorrhage (sICH), stratified by treatment timing (≤ 6 h vs. > 6–24 h from symptom onset). Pooled incidence rates, incidence rate differences (IRD), and incidence rate ratios (IRR) were calculated using random-effects models. Eighteen studies met inclusion criteria. The pooled incidence of symptomatic intracranial hemorrhage (sICH) was 0.19 events per person-year (95% CI: 0.12–0.26) in the early group and 0.23 events per person-year (95% CI: 0.11–0.35) in the late group, with no significant difference between groups (incidence rate difference [IRD] − 0.028; p = 0.33, incidence rate ratio [IRR] 0.88; p = 0.33). For mortality, early EVT showed a significantly lower incidence rate of 0.66 events per person-year (95% CI: 0.51–0.82) compared to 0.77 events per person-year (95% CI: 0.63–0.91) in the late EVT group (IRD − 0.148; p = 0.0012, IRR 0.81; p = 0.0014). Functional independence was more frequent in the early group (1.72; 95% CI: 1.42–2.01) than in the late group (1.45; 95% CI: 0.91–1.98) (IRD 0.32; p < 0.0001, IRR 1.22; p < 0.0001). Heterogeneity was moderate to high across outcomes. The timing of endovascular thrombectomy significantly influences clinical outcomes in acute ischemic stroke. Our analysis shows that early intervention (within 6 h) is associated with a significantly lower mortality rate and a higher likelihood of achieving functional independence at 90 days compared to late intervention (beyond 6 up to 24 h). The incidence of symptomatic intracranial hemorrhage did not differ significantly between the groups, suggesting that late treatment does not increase safety risks. These findings underscore the importance of minimizing treatment delays, while also supporting the continued use of EVT in selected patients beyond the 6-h window.
- Open Access
- 10 June 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (1) , 1173-1187
Quantifying the impact of treatment delays on breast cancer survival outcomes: a comprehensive meta-analysis
Treatment delay in breast cancer care represents a significant concern in oncology, potentially impacting patient survival outcomes. While various factors can contribute to delayed treatment initiation, the quantitative relationship between specific delay intervals and survival remains incompletely understood in breast cancer management. Our study aims to explore the impact of treatment delays on survival outcomes in breast cancer. A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science databases, covering publications from 2000 to 2025. From an initial 6222 records, 18 eligible studies comprising 25 cohorts were included. Hazard ratios (HRs) for all-cause and breast cancer–specific mortality were extracted or calculated for treatment delays of 4, 8, and 12 weeks. Random-effects meta-analyses were performed, and heterogeneity and publication bias were assessed using I 2 statistics, funnel plots, and Egger’s test. This meta-analysis revealed progressively increasing mortality risks with longer treatment delays. For all-cause mortality, HRs increased from 1.12 (95% CI 1.08–1.15) at 4 weeks to 1.25 (95% CI 1.17–1.33) at 8 weeks, and 1.39 (95% CI 1.26–1.53) at 12 weeks. Breast cancer–specific mortality showed more pronounced effects, with HRs of 1.20 (95% CI 1.06–1.36), 1.43 (95% CI 1.11–1.84), and 1.71 (95% CI 1.18–2.49) for 4-, 8-, and 12-week delays, respectively. Analyses combining both survival outcomes demonstrated consistent risk elevation across all time intervals (4 weeks: HR = 1.12, 95% CI 1.09–1.16; 8 weeks: HR = 1.26, 95% CI 1.18–1.34; 12 weeks: HR = 1.41, 95% CI 1.29–1.55). While heterogeneity was significant ( I 2 = 54–92%), no substantial publication bias was detected. Delays in initiating breast cancer treatment are associated with significantly worse survival, particularly for cancer-specific mortality. Each additional 4-week delay increases the hazard of death by over 10%, underscoring the urgency of minimizing delays in diagnosis-to-treatment pathways. These findings have critical implications for healthcare systems, clinical decision-making, and public health policy.
- 10 June 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (1) , 1173-1187
Open AccessQuantifying the impact of treatment delays on breast cancer survival outcomes: a comprehensive meta-analysis
Treatment delay in breast cancer care represents a significant concern in oncology, potentially impacting patient survival outcomes. While various factors can contribute to delayed treatment initiation, the quantitative relationship between specific delay intervals and survival remains incompletely understood in breast cancer management. Our study aims to explore the impact of treatment delays on survival outcomes in breast cancer. A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science databases, covering publications from 2000 to 2025. From an initial 6222 records, 18 eligible studies comprising 25 cohorts were included. Hazard ratios (HRs) for all-cause and breast cancer–specific mortality were extracted or calculated for treatment delays of 4, 8, and 12 weeks. Random-effects meta-analyses were performed, and heterogeneity and publication bias were assessed using I 2 statistics, funnel plots, and Egger’s test. This meta-analysis revealed progressively increasing mortality risks with longer treatment delays. For all-cause mortality, HRs increased from 1.12 (95% CI 1.08–1.15) at 4 weeks to 1.25 (95% CI 1.17–1.33) at 8 weeks, and 1.39 (95% CI 1.26–1.53) at 12 weeks. Breast cancer–specific mortality showed more pronounced effects, with HRs of 1.20 (95% CI 1.06–1.36), 1.43 (95% CI 1.11–1.84), and 1.71 (95% CI 1.18–2.49) for 4-, 8-, and 12-week delays, respectively. Analyses combining both survival outcomes demonstrated consistent risk elevation across all time intervals (4 weeks: HR = 1.12, 95% CI 1.09–1.16; 8 weeks: HR = 1.26, 95% CI 1.18–1.34; 12 weeks: HR = 1.41, 95% CI 1.29–1.55). While heterogeneity was significant ( I 2 = 54–92%), no substantial publication bias was detected. Delays in initiating breast cancer treatment are associated with significantly worse survival, particularly for cancer-specific mortality. Each additional 4-week delay increases the hazard of death by over 10%, underscoring the urgency of minimizing delays in diagnosis-to-treatment pathways. These findings have critical implications for healthcare systems, clinical decision-making, and public health policy.
- Open Access
- 6 June 2025
- Published by Springer Nature in GeroScience
- Vol. 47 (6) , 6955-6983
Age-related and dual task-induced gait alterations and asymmetry: optimizing the Semmelweis Study gait assessment protocol
Gait alterations are recognized as early markers of age-related decline and cognitive impairment. Dual-task assessments, which impose cognitive load while walking, provide valuable insights into gait control limitations and cognitive-motor interactions in aging populations. This study evaluates age-related and cognitive load-induced changes in gait parameters, with a particular focus on asymmetry, and aims to optimize the gait assessment protocol for the Semmelweis Study framework. The Semmelweis Study is a large-scale workplace cohort investigating the determinants of unhealthy aging and promoting healthy brain aging by identifying risk factors and protective mechanisms influencing vascular, metabolic, and neurocognitive decline. As part of this initiative, gait analysis is emerging as a critical tool for assessing functional aging, detecting early signs of mobility and cognitive impairment, and contributing to biological age assessment. A cross-sectional analysis was conducted on adults aged 23 to 87 years using a pressure-sensitive walkway system. Participants were evaluated under single-task conditions (normal walking) and dual-task conditions (walking while performing a concurrent cognitive task). Spatiotemporal gait parameters, asymmetry indices, and dual-task costs were analyzed to assess age-related changes in gait performance and cognitive-motor interactions. Aging was associated with significant reductions in gait speed, step length, and stride length, along with a corresponding increase in gait asymmetry. Dual-task conditions exacerbated these alterations, indicating age-related impairments in cognitive-motor integration. Asymmetry indices were sensitive to aging effects, suggesting their potential as biomarkers for functional decline. The dual-task cost on gait was significantly greater in older adults, reinforcing the interplay between cognitive and motor systems in aging. Age-related gait alterations, particularly under cognitive load, underscore the importance of comprehensive gait assessments in aging research. Our findings contribute to the optimization of the Semmelweis Study gait assessment protocol by identifying key gait parameters that capture functional decline and biological aging. Integrating dual-task gait analysis into large-scale epidemiological studies has the potential to enhance early detection of brain health decline, refine biological age estimation, and guide targeted interventions to support healthy aging and neuromotor resilience.
- 6 June 2025
- Published by Springer Nature in GeroScience
- Vol. 47 (6) , 6955-6983
Open AccessAge-related and dual task-induced gait alterations and asymmetry: optimizing the Semmelweis Study gait assessment protocol
Gait alterations are recognized as early markers of age-related decline and cognitive impairment. Dual-task assessments, which impose cognitive load while walking, provide valuable insights into gait control limitations and cognitive-motor interactions in aging populations. This study evaluates age-related and cognitive load-induced changes in gait parameters, with a particular focus on asymmetry, and aims to optimize the gait assessment protocol for the Semmelweis Study framework. The Semmelweis Study is a large-scale workplace cohort investigating the determinants of unhealthy aging and promoting healthy brain aging by identifying risk factors and protective mechanisms influencing vascular, metabolic, and neurocognitive decline. As part of this initiative, gait analysis is emerging as a critical tool for assessing functional aging, detecting early signs of mobility and cognitive impairment, and contributing to biological age assessment. A cross-sectional analysis was conducted on adults aged 23 to 87 years using a pressure-sensitive walkway system. Participants were evaluated under single-task conditions (normal walking) and dual-task conditions (walking while performing a concurrent cognitive task). Spatiotemporal gait parameters, asymmetry indices, and dual-task costs were analyzed to assess age-related changes in gait performance and cognitive-motor interactions. Aging was associated with significant reductions in gait speed, step length, and stride length, along with a corresponding increase in gait asymmetry. Dual-task conditions exacerbated these alterations, indicating age-related impairments in cognitive-motor integration. Asymmetry indices were sensitive to aging effects, suggesting their potential as biomarkers for functional decline. The dual-task cost on gait was significantly greater in older adults, reinforcing the interplay between cognitive and motor systems in aging. Age-related gait alterations, particularly under cognitive load, underscore the importance of comprehensive gait assessments in aging research. Our findings contribute to the optimization of the Semmelweis Study gait assessment protocol by identifying key gait parameters that capture functional decline and biological aging. Integrating dual-task gait analysis into large-scale epidemiological studies has the potential to enhance early detection of brain health decline, refine biological age estimation, and guide targeted interventions to support healthy aging and neuromotor resilience.
- Open Access
- 23 May 2025
- Published by Springer Nature in GeroScience
- Vol. 47 (5) , 6207-6376
Impacts of systemic milieu on cerebrovascular and brain aging: insights from heterochronic parabiosis, blood exchange, and plasma transfer experiments
Aging is a complex biological process that detrimentally affects the brain and cerebrovascular system, contributing to the pathogenesis of age-related diseases like vascular cognitive impairment and dementia (VCID) and Alzheimer’s disease (AD). While cell-autonomous mechanisms that occur within cells, independent of external signals from neighboring cells or systemic factors, account for some aspects of aging, they cannot explain the entire aging process. Non-autonomous, paracrine and endocrine, pathways also play a crucial role in orchestrating brain and vascular aging. The systemic milieu modulates aging through pro-geronic and anti-geronic circulating factors that mediate age-related decline or confer rejuvenative effects. This review explores the impact of systemic factors on cerebrovascular and brain aging, with a particular focus on findings from heterochronic parabiosis, blood exchange, and plasma transfer experiments. We discuss how these factors influence fundamental cellular and molecular processes of aging and impact cerebrovascular endothelial function, neurovascular coupling mechanisms, blood–brain barrier integrity, neuroinflammation, capillary density, and amyloid pathologies, with significant consequences for cognitive function. Additionally, we address the translational potential and challenges of modifying the systemic milieu to promote brain health and prevent age-related cognitive impairment.
- 23 May 2025
- Published by Springer Nature in GeroScience
- Vol. 47 (5) , 6207-6376
Open AccessImpacts of systemic milieu on cerebrovascular and brain aging: insights from heterochronic parabiosis, blood exchange, and plasma transfer experiments
Aging is a complex biological process that detrimentally affects the brain and cerebrovascular system, contributing to the pathogenesis of age-related diseases like vascular cognitive impairment and dementia (VCID) and Alzheimer’s disease (AD). While cell-autonomous mechanisms that occur within cells, independent of external signals from neighboring cells or systemic factors, account for some aspects of aging, they cannot explain the entire aging process. Non-autonomous, paracrine and endocrine, pathways also play a crucial role in orchestrating brain and vascular aging. The systemic milieu modulates aging through pro-geronic and anti-geronic circulating factors that mediate age-related decline or confer rejuvenative effects. This review explores the impact of systemic factors on cerebrovascular and brain aging, with a particular focus on findings from heterochronic parabiosis, blood exchange, and plasma transfer experiments. We discuss how these factors influence fundamental cellular and molecular processes of aging and impact cerebrovascular endothelial function, neurovascular coupling mechanisms, blood–brain barrier integrity, neuroinflammation, capillary density, and amyloid pathologies, with significant consequences for cognitive function. Additionally, we address the translational potential and challenges of modifying the systemic milieu to promote brain health and prevent age-related cognitive impairment.
- Open Access
- 7 May 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (1) , 793-805
No detectable impact of short-term treatment delays on lung cancer survival
Timely initiation of treatment is a core principle of oncologic care, especially for aggressive cancers such as lung cancer. However, the real-world impact of short-term delays in treatment initiation on survival outcomes in lung cancer remains unclear. This meta-analysis evaluates the association between treatment delays of 4, 8, and 12 weeks and all-cause mortality in lung cancer patients. A systematic search was conducted in PubMed, Scopus, and Web of Science for studies published between 2000 and 2025. Of 5360 screened records, 15 studies were included, comprising 16 cohorts for overall survival of lung cancer patients. Hazard ratios (HRs) for 4-, 8-, and 12-week treatment delays were estimated using random-effects meta-analyses. Heterogeneity was measured with the I 2 statistic, and publication bias was assessed using funnel plots and Egger’s test. No significant association was found between treatment delay and survival at any of the time points. Pooled HRs were 1.00 (95% CI, 0.99–1.02) for a 4-week delay, 1.01 (95% CI, 0.99–1.03) for an 8-week delay, and 1.01 (95% CI, 0.98–1.05) for a 12-week delay. Despite high heterogeneity ( I 2 = 97%), no evidence of publication bias was detected. This meta-analysis found no significant impact of short-term treatment delays (up to 12 weeks) on mortality in lung cancer patients. These findings challenge the assumption that brief delays universally worsen outcomes and underscore the importance of individualized treatment planning and prioritization.
- 7 May 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (1) , 793-805
Open AccessNo detectable impact of short-term treatment delays on lung cancer survival
Timely initiation of treatment is a core principle of oncologic care, especially for aggressive cancers such as lung cancer. However, the real-world impact of short-term delays in treatment initiation on survival outcomes in lung cancer remains unclear. This meta-analysis evaluates the association between treatment delays of 4, 8, and 12 weeks and all-cause mortality in lung cancer patients. A systematic search was conducted in PubMed, Scopus, and Web of Science for studies published between 2000 and 2025. Of 5360 screened records, 15 studies were included, comprising 16 cohorts for overall survival of lung cancer patients. Hazard ratios (HRs) for 4-, 8-, and 12-week treatment delays were estimated using random-effects meta-analyses. Heterogeneity was measured with the I 2 statistic, and publication bias was assessed using funnel plots and Egger’s test. No significant association was found between treatment delay and survival at any of the time points. Pooled HRs were 1.00 (95% CI, 0.99–1.02) for a 4-week delay, 1.01 (95% CI, 0.99–1.03) for an 8-week delay, and 1.01 (95% CI, 0.98–1.05) for a 12-week delay. Despite high heterogeneity ( I 2 = 97%), no evidence of publication bias was detected. This meta-analysis found no significant impact of short-term treatment delays (up to 12 weeks) on mortality in lung cancer patients. These findings challenge the assumption that brief delays universally worsen outcomes and underscore the importance of individualized treatment planning and prioritization.
- Top Cited PapersOpen Access
- 2 May 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (1) , 293-309
Depression increases cancer mortality by 23–83%: a meta-analysis of 65 studies across five major cancer types
Depression is a prevalent but often underrecognized comorbidity among cancer patients. Emerging evidence suggests that psychological distress may adversely impact cancer outcomes, but the magnitude of its effect on survival remains unclear. This meta-analysis evaluates the association between depression diagnosed after cancer diagnosis and cancer-specific and all-cause mortality across major cancer types. A systematic search of PubMed, Web of Science, Google Scholar, and the Cochrane Library was conducted to identify cohort studies examining the impact of depression on cancer mortality. Studies were included if they assessed clinically diagnosed depression or depressive symptoms using validated scales and reported hazard ratios (HRs) for mortality outcomes. A random-effects meta-analysis was performed to pool HR estimates, with heterogeneity assessed via Cochran’s Q and I 2 statistics. Funnel plots and Egger’s test were used to evaluate publication bias. A total of 65 cohort studies were included. Depression was associated with significantly increased cancer-specific mortality in colorectal cancer (HR 1.83, 95% CI 1.47–2.28), breast cancer (HR 1.23, 95% CI 1.13–1.34), lung cancer (HR 1.59, 95% CI 1.36–1.86), and prostate cancer (HR 1.74, 95% CI 1.36–2.23). When considering mixed cancer types, depression was linked to a 38% increased risk of cancer mortality (HR 1.38, 95% CI 1.20–1.60). Significant heterogeneity was observed across studies ( I 2 range 56–98%), suggesting variations in study populations and methodologies. Sensitivity analyses confirmed the robustness of the findings, and trial sequential analysis indicated sufficient evidence for a conclusive association. Depression after cancer diagnosis is associated with a significantly increased risk of cancer-specific mortality across multiple cancer types. These findings highlight the urgent need for integrating routine mental health screening and interventions into oncology care. Future research should focus on mechanistic pathways and targeted interventions to mitigate the negative impact of depression on cancer survival.
- 2 May 2025
- Published by Springer Nature in GeroScience
- Vol. 48 (1) , 293-309
Top Cited PapersOpen AccessDepression increases cancer mortality by 23–83%: a meta-analysis of 65 studies across five major cancer types
Depression is a prevalent but often underrecognized comorbidity among cancer patients. Emerging evidence suggests that psychological distress may adversely impact cancer outcomes, but the magnitude of its effect on survival remains unclear. This meta-analysis evaluates the association between depression diagnosed after cancer diagnosis and cancer-specific and all-cause mortality across major cancer types. A systematic search of PubMed, Web of Science, Google Scholar, and the Cochrane Library was conducted to identify cohort studies examining the impact of depression on cancer mortality. Studies were included if they assessed clinically diagnosed depression or depressive symptoms using validated scales and reported hazard ratios (HRs) for mortality outcomes. A random-effects meta-analysis was performed to pool HR estimates, with heterogeneity assessed via Cochran’s Q and I 2 statistics. Funnel plots and Egger’s test were used to evaluate publication bias. A total of 65 cohort studies were included. Depression was associated with significantly increased cancer-specific mortality in colorectal cancer (HR 1.83, 95% CI 1.47–2.28), breast cancer (HR 1.23, 95% CI 1.13–1.34), lung cancer (HR 1.59, 95% CI 1.36–1.86), and prostate cancer (HR 1.74, 95% CI 1.36–2.23). When considering mixed cancer types, depression was linked to a 38% increased risk of cancer mortality (HR 1.38, 95% CI 1.20–1.60). Significant heterogeneity was observed across studies ( I 2 range 56–98%), suggesting variations in study populations and methodologies. Sensitivity analyses confirmed the robustness of the findings, and trial sequential analysis indicated sufficient evidence for a conclusive association. Depression after cancer diagnosis is associated with a significantly increased risk of cancer-specific mortality across multiple cancer types. These findings highlight the urgent need for integrating routine mental health screening and interventions into oncology care. Future research should focus on mechanistic pathways and targeted interventions to mitigate the negative impact of depression on cancer survival.
- Top Cited PapersOpen Access
- 12 April 2025
- Published by Springer Nature in GeroScience
- Vol. 47 (3) , 5235-5255
Exercise and survival benefit in cancer patients: evidence from a comprehensive meta-analysis
Cancer remains a major global health challenge, and growing evidence suggests that physical activity is a key modifiable factor that may improve survival outcomes in cancer patients. However, a comprehensive, large-scale synthesis of the effects of post-diagnosis physical activity across multiple cancer types remains lacking. This meta-analysis aims to systematically evaluate the association between physical activity and survival in patients diagnosed with breast, lung, prostate, colorectal, and skin cancers. We conducted a comprehensive search in PubMed, Web of Science, Scopus, and Cochrane Library for studies on physical activity and cancer survival. Eligible studies (January 2000–November 2024) included adults (≥ 18 years) with breast, lung, prostate, colorectal, or skin cancer. Only prospective cohort and case–control studies reporting hazard ratios (HRs) with 95% confidence intervals (CIs) for overall or cancer-specific mortality were included, with a minimum sample size of 100 and at least six months of follow-up. Meta-analysis was performed using metaanalysisonline.com, applying random-effects models and assessing heterogeneity via the I2 statistic. Sensitivity analyses and publication bias (Egger’s test, funnel plots) were evaluated. The meta-analysis included 151 cohorts with almost 1.5 million cancer patients. Post-diagnosis physical activity was associated with significantly lower cancer-specific mortality across all five cancer types. The greatest benefit was observed in breast cancer, with a pooled hazard ratio (HR) of 0.69 (95% CI: 0.63–0.75), followed by prostate cancer (HR: 0.73, 95% CI: 0.62–0.87). Lung cancer patients who engaged in physical activity had a 24% lower risk of cancer-specific death (HR: 0.76, 95% CI: 0.69–0.84), while colorectal cancer patients experienced a similar benefit (HR: 0.71, 95% CI: 0.63–0.80). In skin cancer, physical activity was associated with a non-significant reduction in mortality (HR: 0.86, 95% CI: 0.71–1.05). These findings provide robust evidence supporting the survival benefits of post-diagnosis physical activity in cancer patients, particularly for breast, prostate, lung, and colorectal cancers. The results underscore the potential for incorporating structured physical activity interventions into oncological care to improve long-term patient outcomes.
- 12 April 2025
- Published by Springer Nature in GeroScience
- Vol. 47 (3) , 5235-5255
Top Cited PapersOpen AccessExercise and survival benefit in cancer patients: evidence from a comprehensive meta-analysis
Cancer remains a major global health challenge, and growing evidence suggests that physical activity is a key modifiable factor that may improve survival outcomes in cancer patients. However, a comprehensive, large-scale synthesis of the effects of post-diagnosis physical activity across multiple cancer types remains lacking. This meta-analysis aims to systematically evaluate the association between physical activity and survival in patients diagnosed with breast, lung, prostate, colorectal, and skin cancers. We conducted a comprehensive search in PubMed, Web of Science, Scopus, and Cochrane Library for studies on physical activity and cancer survival. Eligible studies (January 2000–November 2024) included adults (≥ 18 years) with breast, lung, prostate, colorectal, or skin cancer. Only prospective cohort and case–control studies reporting hazard ratios (HRs) with 95% confidence intervals (CIs) for overall or cancer-specific mortality were included, with a minimum sample size of 100 and at least six months of follow-up. Meta-analysis was performed using metaanalysisonline.com, applying random-effects models and assessing heterogeneity via the I2 statistic. Sensitivity analyses and publication bias (Egger’s test, funnel plots) were evaluated. The meta-analysis included 151 cohorts with almost 1.5 million cancer patients. Post-diagnosis physical activity was associated with significantly lower cancer-specific mortality across all five cancer types. The greatest benefit was observed in breast cancer, with a pooled hazard ratio (HR) of 0.69 (95% CI: 0.63–0.75), followed by prostate cancer (HR: 0.73, 95% CI: 0.62–0.87). Lung cancer patients who engaged in physical activity had a 24% lower risk of cancer-specific death (HR: 0.76, 95% CI: 0.69–0.84), while colorectal cancer patients experienced a similar benefit (HR: 0.71, 95% CI: 0.63–0.80). In skin cancer, physical activity was associated with a non-significant reduction in mortality (HR: 0.86, 95% CI: 0.71–1.05). These findings provide robust evidence supporting the survival benefits of post-diagnosis physical activity in cancer patients, particularly for breast, prostate, lung, and colorectal cancers. The results underscore the potential for incorporating structured physical activity interventions into oncological care to improve long-term patient outcomes.